Results 71 to 80 of about 17,204,946 (352)

Plasma lipids and prothrombin time in rats fed palm oil and other commonly used fats in Egypt

Grasas y Aceites, 1993
Sprague-Dawley rats were fed for a total period of 8 weeks on six diets that were different in the source of their fat content. The fat content was provided either, palm oil or palm olein or corn oil or hydrogenated fat, or frying palm oil and mixture of
Mona M. Hussein, Fawzy M. Salama, Karina M. Ebada   +2 more
doaj   +1 more source

Neck‐vein thrombosis during spaceflight

British Journal of Clinical Pharmacology, EarlyView.
Spaceflight imposes unique environmental challenges, including weightlessness, increased radiation exposure and confinement, which can lead to unexpected health effects. One such example is neck‐vein thrombosis, a condition rarely seen on Earth without predisposing factors such as venous catheters or infections.
Ulrich Limper, Jens Jordan
wiley   +1 more source

Clinical Utilisation of Cryoprecipitate at a Tertiary Care Centre in Telangana, India: A Quasi-experimental Study [PDF]

National Journal of Laboratory Medicine
Introduction: Cryoprecipitate is a slushy product derived from Fresh Frozen Plasma (FFP) through centrifugation at specific temperatures and speeds. It is rich in factor VIII or antihaemorrhagic factor, fibrinogen, and minor amounts of other clotting ...
Sudhir Kumar Vujhini, Kandukuri Mahesh Kumar, Murali Krishna Bogi, Shanthi Bonagiri   +3 more
doaj   +1 more source

Comparison of in‐Hospital Complication Rates After Transcatheter Aortic Valve Replacement in Patients With Bicuspid Versus Tricuspid Aortic Valves: A Retrospective Cohort Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Transcatheter aortic valve replacement (TAVR) has become a popular alternative to surgical aortic valve replacement (SAVR) for patients with valvular heart disease (VHD), particularly for those with aortic anomalies. Aims The study aimed to compare the risks of post‐TAVR complications between patients with bicuspid and tricuspid ...
Tingxi Zhu, Jiawei Luo, Xuan Huang, Lulu Liu, Kehan Li, Wei He, Xiaobo Zhou, Yingqiang Guo, Xiaoyan Yang   +8 more
wiley   +1 more source

Left Ventricular Apical Thrombus in Apical Hypertrophic Cardiomyopathy Without Aneurysm or Arrhythmia: A Case Report

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Apical hypertrophic cardiomyopathy (ApHCM) is a rare variant of hypertrophic cardiomyopathy, typically associated with a benign course. However, complications such as ventricular arrhythmias, apical aneurysms, and thrombus formation may occur. Left ventricular (LV) thrombus is an unusual finding in ApHCM, especially in patients with preserved ...
Ibrahim Antoun, Jeffrey Khoo, Sanjay S. Bhandari   +2 more
wiley   +1 more source

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

Clinical Pharmacology &Therapeutics, EarlyView.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou, Emily Bozenhardt, Gregory E. Alexander, Matthew L. Zierhut, Samira Merali, Antoinette Ajavon‐Hartmann, Peter Zannikos, Hyunmoon Back, EunYoung Suh, Navin Goyal, Mahesh N. Samtani, Alexei N. Plotnikov, Chandni Valiathan   +12 more
wiley   +1 more source

Nomogram for predicting bleeding events in nonvalvular atrial fibrillation patients receiving rivaroxaban: A retrospective study

Health Science Reports
Background and Aims To construct a bleeding events prediction model of nonvalvular atrial fibrillation (NVAF) patients receiving rivaroxaban. Methods We conducted a retrospective cohort study in patients with NVAF who received rivaroxaban from June 2017 ...
Chang Cao, Yijiao Xu, Weiwen Jiang, Shujing Wu, Yun Shen, Xiaotong Xia, Lumin Wang, Huijun Zhang, Hongni Jiang, Xiaoyu Li, Xiaoye Li, Yanrong Ye   +11 more
doaj   +1 more source

Hemothorax in a Medical Intensive Care Unit: Incidence, Comorbidity and Prognostic Factors

Journal of the Formosan Medical Association, 2010
There is a lack of data regarding the occurrence of hemothorax in medical intensive care units (ICUs). The purpose of this study was to investigate the incidence, comorbidity and prognostic factors of hemothorax in medical ICU patients.
Chung-Yu Chen, Chia-Lin Hsu, Chia-Hsuin Chang, Kuan-Yu Chen, Chong-Jen Yu, Pan-Chyr Yang   +5 more
doaj   +1 more source

Quantitative Systems Toxicology Predicts Ivacaftor‐Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity

Clinical Pharmacology &Therapeutics, EarlyView.
Cystic fibrosis (CF) is a chronic hereditary disease that affects tens of thousands of people worldwide. The introduction of CFTR modulator therapies such as elexacaftor/tezacaftor/ivacaftor (ETI) has significantly improved the quality of life of people with CF.
Alan Shi, Cole Cornwell, Kyunghee Yang, Paul M. Beringer   +3 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source